Randomized clinical trial with two doses (100 and 40 ml) of Stronger Neo-Minophagen C in chinese patients with chronic hepatitis B

Hepatology Research

Volumn 24, Issue 3, 2002, Pages 220-227

  Zhang, Lingxia ^a   Wang, Baoen ^a  

^a Chinese Medical Association   (China)

Author keywords

Glycyrrhizin; Hepatitis B; Stronger Neo Minophagen C

Indexed keywords

ALANINE AMINOTRANSFERASE; AMMONIA; ANTIVIRUS AGENT; CHINESE DRUG; CORTICOSTEROID; CYSTEINE; GLYCERIC ACID; GLYCINE; GLYCYRON TAB; GLYCYRRHIZIC ACID; INTERFERON; LAMIVUDINE; METHIONINE; NEOMINOPHAGEN C; POTASSIUM; SPIRONOLACTONE; STRONGER NEO MINOPHAGEN C; SULFITE; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHINA; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HOSPITAL; HUMAN; HYPERTENSION; HYPOKALEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TABLET; THORAX DISEASE; TREATMENT OUTCOME;

EID: 0036847451     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(02)00086-4     Document Type: Article

References (17)

1. Yamamoto S, Maekawa Y, Imamura M, et al. Treatment of hepatitis with the antiallergic drug, Stronger Neo-Minophagen C. Clin Med Pediatr 1958;13:73-5 in Japanese.
2. Suzuki H, Ohta Y, Takino T, et al. Effects of Stronger Neo-Minophagen C on biochemical tests in patients with chronic hepatitis-double blind trial. Igaku-no-Ayumi 1977;102:562-78 in Japanese.
3. Zhang L, Cui Z, Wang B. Therapeutic effects of Stronger Neo-Minophagen C (SNMC) in patients with chronic liver disease. Hepatol Res 2000;16:145-54.
4. Hino K, Miyakawa H, Takahashi J, et al. Large-dose administration of Stronger Neo-Minophagen C (SNMC) for the treatment of chronic active hepatitis. Kan-Tan-Sui 1986;13:797-807 in Japanese.
5. Iino S, Tango T, Matsushima T, et al. Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis. Hepatol Res 2001;19:31-40.
6. van Rossum TG, Vulto AG, Hop WC, Brouwer JT, Niesters HG, Schalm SW. Intravenous glycyrrhizin for the treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial. J Gastroenterol Hepatol 1999;14:1093-9.
7. Yao G, Wang G, Cui Z, Yao J, Zeng M. A randomized double-blind placebo-controlled study of lamibudine in the treatment of patients with chronic hepatitis B virus infection. Chin Med J 1999;112:387-91.
8. van Rossum TGV, Vulto AG, Hop WCJ, Schalm SW. Glycyrrhizin induced reduction of ALT in European patients with chronic hepatitis C. Am J Gastroenterol 2001;91:2432-7.
9. Tanikawa K, Ichida F, Suzuki H, et al. A placebo-controlled double-blind study of lamibudine in chronic hepatitis B. Kan-Tan-Sui 1998;36:447-64 in Japanese.
10. van Rossum TG, Vulto AG, de Man RA, Brouwer JT, Schalm SW. Review article: glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment Pharmacol Ther 1998;12:199-205.
11. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993;119:312-23.
12. Stewart PM, Wallace AM, Valentino R, Burt D, Shackleton CH, Edeards CR. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet 1987;ii:821-4.
13. van Rossum TGJ, de Jong FH, Hop WCJ, Boomsma F, Schalm SW. 'Pseudo-aldosteronism' induced by intravenous glycyrrhizin treatement of chronic hepatitis C patients. J Gastroenterol Hepatol 2001;16:789-95.
14. Leung N. Liver disease-significant improvement with lamivudine. J Med Virol 2000;61:380-5.
15. Chayama K, Suzuki Y, Kobayashi M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy. Hepatology 1998;27:1711-6.
16. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30:567-72.
17. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.